Claims

1. A compound comprising a cyclic peptide of formula (Ia)



(Ia)

or a cyclic peptide of formula (Ib)



(Ib)

each optionally comprising an N-terminal modification group A attached to Xaa1, and each optionally comprising a C-terminal group C-term attached to Xaa11,

wherein

the peptide sequence is drawn from left to right in N- to C-terminal direction,

Xaa1 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises an acidic or polar group, or

Xaa1 is a residue of an aliphatic carboxylic acid comprising an acidic or polar group at the ω-position,

wherein the carbonyl group of Xaa1 is covalently attached to the α-nitrogen atom of Xaa2,

Xaa2 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a heteroaryl ring or an aryl ring,

wherein the carbonyl group of Xaa2 is covalently attached to the α-nitrogen atom of Xaa3,

Xaa3 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a heteroaryl ring or an aryl ring,

wherein the carbonyl group of Xaa3 is covalently attached to the α-nitrogen atom of Xaa4,

Xaa4 is a residue of an α-amino acid optionally comprising a Z group or is a residue of an N-alkylated α-amino acid optionally comprising a Z group,

wherein the carbonyl group of Xaa4 is covalently attached to the α-nitrogen atom of Xaa5,

Xaa5 is a residue of an α-amino acid optionally comprising a Z group,

wherein the carbonyl group of Xaa5 is covalently attached to the α-nitrogen atom of Xaa6,

Xaa6 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a branched aliphatic group,

wherein the carbonyl group of Xaa6 is covalently attached to the α-nitrogen atom of Xaa7,

Xaa7 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprising a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising a sulfur atom and a nitrogen atom,

wherein the carbonyl group of Xaa7 is covalently attached to the α-nitrogen atom of Xaa8,

Xaa8 is a residue of an α-amino acid optionally comprising a Z group,

wherein the carbonyl group of Xaa8 is covalently attached to the α-nitrogen atom of Xaa9,

Xaa9 is a residue of an α-amino acid,

wherein the carbonyl group of Xaa9 is covalently attached to the α-nitrogen atom of Xaa10,

Xaa10 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a branched aliphatic group or an unsubstituted aromatic ring,

wherein the carbonyl group of Xaa10 is covalently attached to the α-nitrogen atom of Xaa11, if Xaa11 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising a sulfur atom and a nitrogen atom, or, if Xaa11 is a residue of an aliphatic bis-nucleophile, wherein the first nucleophile of the bis-nucleophile is a nitrogen atom and the second nucleophile of the bis-nucleophile is a heteroatom, wherein the heteroatom is selected from the group comprising a sulfur atom and a nitrogen atom, to the first nucleophile,

Xaa11 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising a sulfur atom and a nitrogen atom, or

Xaa11 is a residue of an aliphatic bis-nucleophile, wherein the first nucleophile of the bis-nucleophile is a nitrogen atom and the second nucleophile of the bis-nucleophile is a heteroatom, wherein the heteroatom is selected from the group comprising a sulfur atom and a nitrogen atom,

wherein Xaa7 and Xaa11 are indirectly linked or directly covalently linked to each other forming a macrocyclic ring,

wherein if Xaa7 and Xaa11 are indirectly linked forming a cyclic peptide of formula (Ia), the heteroatom of Xaa7 and the heteroatom of Xaa11 are linked through a ring interspersed between the heteroatom of Xaa7 and the heteroatom of Xaa11 forming Yc, wherein the ring is a heteroaryl ring, an aryl ring optionally comprising a Z group or a heterocyclic ring, wherein the heteroatom is each and individually selected from the group consisting of a sulfur atom and a nitrogen atom, wherein if the heteroatom of Xaa7 is a sulfur atom, a thioether bond covalently links Xaa7 to the ring, if the heteroatom of Xaa7 is a nitrogen atom, an amine bond or an amide bond covalently links Xaa7 to the ring, if the heteroatom of Xaa11 is a sulfur atom, a thioether bond covalently links Xaa11 to the ring, and if the heteroatom of Xaa11 is a nitrogen atom, an amine bond or an amide bond covalently links Xaa11 to the ring, or

wherein if Xaa7 and Xaa11 are directly covalently linked forming a cyclic peptide of formula (Ib), the heteroatom of Xaa7 is a sulfur atom and the heteroatom of Xaa11 is a sulfur atom forming a disulfide bond,

and wherein

if present, the N-terminal modification group A is selected from the group comprising

a) a Z group, wherein a linker is optionally interspersed between the Z group and Xaa1,

b) a blocking group AblN,

c) a residue of an amino acid optionally comprising a Z group and optionally comprising a blocking group AblN, and

d) an N-terminal dipeptide group comprising a residue of a first amino acid and a residue of a second amino acid, wherein the residue of the first amino acid is the N-terminal amino acid residue and the residue of the second amino acid is the C-terminal amino acid residue,

wherein the residue of the first amino acid optionally comprises a blocking group AblN,

wherein the residue of the first amino acid and the residue of the second amino acid are covalently attached to each other,

wherein the residue of the second amino acid is covalently attached to the residue of Xaa1 or a linker is interspersed between the second amino acid and the residue of Xaa1,

and wherein a Z group is optionally covalently attached to the residue of the first amino acid and/or a Z group is optionally covalently attached to the residue of the second amino acid,

and wherein

if present, the C-terminal group C-term is selected from the group comprising

a) a residue of an amino acid,

wherein the residue of an amino acid is covalently attached to Xaa11 or a linker is interspersed between the residue of an amino acid and Xaa11,

wherein a Z group is optionally covalently attached to the residue of an amino acid,

and wherein the residue of an amino acid comprises a blocking group AblC,

b) a C-terminal dipeptide group, wherein the C-terminal dipeptide group comprises a residue of a first amino acid and a residue of a second

amino acid, wherein the residue of the first amino acid is the N-terminal amino acid residue and the residue of the second amino acid is the C-terminal amino acid residue,

wherein the residue of the first amino acid and the residue of the second amino acid are covalently attached to each other,

wherein the residue of the first amino acid is covalently attached to the residue of Xaa11 or a linker is interspersed between the residue of the first amino acid and the residue of Xaa11,

wherein a Z group is optionally covalently attached to the residue of the first amino acid and/or a Z group is optionally covalently attached to the residue of the second amino acid,

and wherein the residue of the second amino acid comprises a blocking group AblC;

c) a Z group; and

d) a blocking group AblC.

2. The compound of claim 1,

wherein

Xaa1 is (a) a residue of an α-amino acid comprising a side chain, wherein the side chain comprises an acidic or polar group, or

(b) a residue of an amino acid of formulae (IIa), (IIb) or (IIc),



(IIa),


(IIb),


(IIc),

wherein

R^{1a} is selected from the group consisting of –NH–, H, –NH((C_1-C_4)alkyl)–, OH, and (C_1-C_4)alkyl,

wherein if R^{1a} is selected from the group consisting of –NH– and -NH((C_1-C_4)alkyl)–, the N-terminal modification group A is covalently attached to the nitrogen atom of R^{1a},

and if R^{1a} is selected from the group consisting of H, OH or $(C_1\text{-}C_4)$alkyl, the N-terminal modification group A is absent,

R^{1b} is selected from the group consisting of CO_2H, SO_3H, OPO_3H_2, $CONH_2$ and OH,

R^{1c} is selected from the group consisting of H, OH and $(C_1\text{-}C_2)$alkyl under the proviso that R^{1b} is selected from the group consisting of CO_2H, SO_3H and $CONH_2$,

or is selected from the group consisting of H and $(C_1\text{-}C_2)$alkyl under the proviso that R^{1b} is selected from the group consisting of OH and OPO_3H_2,

R^{1d} is selected from the group consisting of H and $(C_1\text{-}C_2)$alkyl,

R^{1e} is selected from the group consisting of H, OH and $(C_1\text{-}C_2)$alkyl,

R^{1f} is selected from the group consisting of H and $(C_1\text{-}C_2)$alkyl,

and the carbonyl group of Xaa1 is covalently attached to the α-nitrogen atom of Xaa2,

Xaa2 is (a) a residue of an α-amino acid of formulae (IIIa) or (IIIb),



(IIIa),



(IIIb),

wherein

X^{2a} is selected from the group consisting of NH, NCH_3 and S,

X^{2b} is selected from the group consisting of N, CH, CF and C-CH_3,

R^{2a} is selected from the group consisting of H, a halogen, methyl and OCH_3,

R^{2b} is selected from the group consisting of H, a halogen, methyl and OCH_3,

R^{2c} is selected from the group consisting of H, OH, a halogen, methyl and OCH_3,

R^{2d} is selected from the group consisting of H, a halogen, methyl and OCH_3, wherein the halogen is selected from the group consisting of F, Cl and Br,

R^{2e} is selected from the group consisting of H, a halogen and methyl,

R^{2f} is selected from the group consisting of H and OCH_3,

R^{2g} is selected from the group consisting of H, OH, methyl and OCH_3,

or (b), under the proviso that Xaa3 is of formulae (IVa) or (IVb), Xaa2 Xaa2 is a residue of an amino acid of formula (IIIc)



(IIIc),

wherein

R^{2h} is selected from the group consisting of H, methyl, CF_3, OH, OCH_3, OCF_3, $CONH_2$ and a halogen,

R^{2i} is selected from the group consisting of H, methyl, $C(CH_3)_3$, CF_3, OH, OCH_3, OCH_2CH_3, OCF_3, $CONH_2$, CO_2H and a halogen,

R^{2k} is selected from the group consisting of H, methyl, CF_3, OH, OCH_3, OCF_3, $CONH_2$ and a halogen,

R^{2m} is selected from the group consisting of H, methyl, CF_3, OH, OCH_3, OCF_3, $CONH_2$ and a halogen,

and the carbonyl group of Xaa2 is covalently attached to the α-nitrogen atom of Xaa3,

Xaa3 is (a) a residue of an amino acid of formulae (IVa) or (IVb,



(IVa),



(IVb)

wherein

X^{3a} is selected from the group consisting of NH, NCH_3 and S,

X^{3b} is selected from the group consisting of C-H, C-F, C-Cl, C-Br, C-CH_3, C-OCH_3 and N,

X^{3c} is selected from the group consisting of C and N,

R^{3b} is selected from the group consisting of H, a halogen, methyl and OCH_3,

R^{3c} is selected from the group consisting of H, a halogen, methyl and OCH_3,

R^{3d} is selected from the group consisting of H, a halogen, methyl and OCH_3,

R^{3e} is selected from the group consisting of H, a halogen and methyl,

R^{3f} is selected from the group consisting of H and OCH_3,

R^{3g} is selected from the group consisting of H, F, OH, methyl and OCH_3,

or (b) under the proviso that Xaa2 is an amino acid residue of formula (IIIa), Xaa3 is a residue of an amino acid of formulae (IVc) or (IVd)



(IVc),



(IVd),

wherein

R^{3h} is selected from the group consisting of a halogen, OH, methyl, CF_3, OCH_3, OCF_3 and $CONH_2$,

R^{3i} is selected from the group consisting of a halogen, OH, methyl, CF_3, OCH_3, OCF_3 and $CONH_2$,

and the carbonyl group of Xaa3 is covalently attached to the α-nitrogen atom of Xaa4,

Xaa4 is (a) a residue of a cyclic non-aromatic α-amino acid,

or (b) a residue of an N-alkylated amino acid

or (c) Xaa4 is a residue of a bicyclic non-aromatic amino acid,

and the carbonyl group of Xaa4 is covalently attached to the α-nitrogen atom of Xaa5,

Xaa5 is (a) a residue of an α-amino acid optionally comprising a Z group, wherein the α-nitrogen atom of the α-amino acid is optionally substituted by (C_1-C_4)alkyl or (b) a cyclic α-amino acid, and the carbonyl group of Xaa5 is covalently attached to the α-nitrogen atom of Xaa6,

Xaa6 is a residue of an amino acid of formula (VIIa)



(VIIa),

wherein

p is 1, 0 or 2,

R^{6a} is selected from the group consisting of (C_1-C_2)alkyl,

R^{6b} is methyl,

R^{6c} is H, if p is 0,

or is selected from the group consisting of H and methyl, if p is 1 or 2,

and the carbonyl group of Xaa6 is covalently attached to the α-nitrogen atom of Xaa7,

Xaa7 is a residue of an α-amino acid of formula (VIIIa)



(VIIIa),

wherein

X^7 comprises the heteroatom and is selected from the group consisting of –S– and –NH–,

q is 1 or 2,

and the carbonyl group of Xaa7 is covalently attached to the α-nitrogen atom of Xaa8,

Xaa8 is (a) a residue of an aliphatic cyclic α-amino acid, of an aliphatic heterocyclic α-amino acid or of an aliphatic cyclic α-amino acid comprising an annulated aromatic ring,

or (b) a residue of an α-amino acid or an α-alkyl-α-amino acid,

and the carbonyl group of Xaa8 is covalently attached to the α-nitrogen atom of Xaa9,

Xaa9 is a residue of an acyclic α-amino acid, whereby the acyclic α-amino acid is in L-configuration and the carbonyl group of Xaa9 is covalently attached to the α-nitrogen atom of Xaa10,

Xaa10 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a branched aliphatic group or an unsubstituted aromatic ring,

Xaa11 is (a) a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected form the group comprising a sulfur atom and a nitrogen atom,

or (b) Xaa11 is a residue of an aliphatic bis-nucleophile, wherein the first nucleophile of the bis-nucleophile is a nitrogen atom and the second nucleophile of the bis-nucleophile is a heteroatom, wherein the heteroatom is selected from the group comprising a sulfur atom and a nitrogen atom,

.

3. The compound of any one of claims 1 to 2,

wherein

Xaa4 is (a) a residue of an amino acid of formula (Va)



(Va),

wherein

R^{4a} is selected from the group consisting of H, OH, methyl and CF_3,

R^{4b} is selected from the group consisting of H and methyl,

X^4 is selected from the group consisting of CHR^{4c}, S and O,

wherein R^{4c} is absent or is selected from the group consisting of NH_2, OH, H, NHR^{4d}, methyl and F,

wherein R^{4d} is selected from the group consisting of Ac and a Z group,

m is 1 or 2,

or (b) a residue of an amino acid of formula (Vb)



(Vb),

wherein

n is 0, 1, 2, 3, 4, or 5,

R^{4e} is, if n is 0, selected from the group consisting of H, methyl, an aryl ring, COOH, $CONH_2$ and $C(=O)R^{4h}$,

or is, if n is 1, 2, 3, 4 or 5, selected from the group consisting of H, methyl, an aryl ring, OH, NH_2, COOH, $CONH_2$ and $C(=O)R^{4h}$,

R^{4f} is selected from the group consisting of H and $(C_1$-$C_2)$alkyl,

R^{4g} is selected from the group consisting of H and methyl,

R^{4h} is a Z group,

or (c) Xaa4 is a residue of an amino acid of formula (Vc)


(Vc),

wherein

o is 1 or 2,

and the carbonyl group of Xaa4 is covalently attached to the α-nitrogen atom of Xaa5,

Xaa8 is (a) a residue of an amino acid of formula (IXa) or (IXb),


(IXa),


(IXb),

wherein

X^8 is selected from the group consisting of NR^{8a}, O, NH, and CH_2, wherein R^{8a} is a Z group or R^{8a} is acetyl,

r is 2 or 1,

s is 1 or 2,

t is 1 or 2,

or (b) a residue of an an amino acid of formula (IXc),


(IXc),

wherein

R^{8b} is selected from the group consisting of H, OH, NH_2, NHR^{8e}, $(C_1$-$C_2)$alkyl, COOH, $CONH_2$, an aryl ring and a heteroaryl ring, wherein R^{8e} is a Z group,

R^{8c} is selected from the group consisting of H and methyl, if R^{8b} is selected from the group consisting of OH, NH_2 and NHR^{8e},

or is selected from the group consisting of H, methyl and OH, if R^{8b} is selected from the group consisting of H, $(C_1\text{-}C_2)$alkyl, COOH, $CONH_2$, an aryl ring and a heteroaryl ring,

R^{8d} is selected from the group consisting of H and $(C_1\text{-}C_2)$alkyl,

u is 0, 1, 2, 3, 4, or 5,

and the carbonyl group of Xaa8 is covalently attached to the α-nitrogen atom of Xaa9,

Xaa10 is a residue of an α-amino acid of formula (XIa),



(XIa),

wherein

R^{10a} is selected from the group consisting of $(C_1\text{-}C_2)$alkyl and phenyl,

R^{10b} is selected from the group consisting of methyl and H,

R^{10c} is selected from the group consisting of H and methyl,

w is 0 or 1,

and the carbonyl group of Xaa10 is covalently attached to the α-nitrogen of Xaa11, if Xaa11 is a residue of an α-amino acid comprising a side chain, wherein the side chain comprises a nucleophilic group, wherein the nucleophilic group comprises a heteroatom, wherein the heteroatom is selected from the group comprising S and N, or, if Xaa11 is a residue of an aliphatic bis-nucleophile, wherein the first nucleophile of the bis-nucleophile is a nitrogen atom and the second nucleophile of the bis-nucleophile is a heteroatom, wherein the heteroatom is selected from the group comprising S and N, to the first nucleophile,

Xaa11 is of formula (XIIa)



(XIIa),

wherein

X^{11} comprises the heteroatom and is selected from the group consisting of –S– and –NH–,

R^{11b} is selected from the group consisting of $C(=O)R^{11c}$, $CONH_2$, CO_2H, CH_2OH and H, wherein R^{11c} is C-term,

x is 1 or 2,

and wherein if R^{1a} in Xaa1 is selected from the group consisting of –NH– and -NH((C_1-C_4)alkyl)–, the N-terminal modification group A is covalently attached to the nitrogen atom in R^{1a}, wherein the N-terminal modification group A is

a) a Z group, wherein a linker is optionally interspersed between the Z group and Xaa1, or

b) a blocking group AblN, wherein the blocking group AblN is selected from the group consisting of acetyl, a structure of formula (AblN-Ia) and Nph2p,



(AblN-Ia),

wherein

R^{Abl1} is selected from the group consisting of H, OH and a halogen,

or

c) the residue of an amino acid as defined in claim 1, wherein the amino acid is an α-amino acid,

wherein the residue of an amino acid optionally comprises a Z group covalently attached to the side chain of the residue of an amino acid and optionally comprises a Z group covalently attached to the α-amino group of the residue of an amino acid, or

wherein the residue of an amino acid optionally comprises a blocking group AblN covalently attached to the α-amino group of the residue of an amino acid,

and wherein the carbonyl group of the residue of an amino acid is covalently attached to the nitrogen atom in R^{1a} of residue Xaa1,

and

d) the N-terminal dipeptide group as defined in claim 1,

wherein the residue of the first amino acid, the residue of the second amino acid or both the residues of the first and of the second amino acid optionally comprise a Z group,

wherein an optional blocking group AblN is covalently attached to the α-amino group of the residue of the first amino acid,

and wherein a linker is optionally interspersed between the residue of the second amino acid and the residue of Xaa1,

wherein if the interspersed linker is absent, the carbonyl group of the residue of the first amino acid is covalently attached to the α-nitrogen of the residue of the second amino acid and the carbonyl group of the residue of the second amino acid is covalently attached to the nitrogen atom in R^{1a},

or wherein if the interspersed linker is present, the carbonyl group of the residue of the first amino acid is covalently attached to the α-nitrogen of the residue of the second amino acid and the carbonyl group of the residue of the second amino acid is covalently attached to a nitrogen atom of the linker and a carbonyl group of the linker is covalently attached to the nitrogen atom in R^{1a},

wherein if Xaa11 is a residue of an amino acid of formula (XIIa), wherein R^{11b} is $C(=O)R^{11c}$, and R^{11c} is the C-terminal group C-term, C-term is selected from the group comprising

a) the residue of an amino acid as defined in claim 1, wherein the amino acid is an α-amino acid,

optionally comprising a Z group and optionally comprising a linker interspersed between the residue of Xaa11 and the residue of an amino acid,

wherein if the interspersed linker is absent, the carbonyl group R^{11b} of residue Xaa11 is covalently attached to the α-nitrogen of the residue of an amino acid,

or wherein if the interspersed linker is present, the carbonyl group in R^{11b} of residue Xaa11 is covalently attached to a nitrogen atom of the linker, a carbonyl group of the linker is covalently attached to the α-nitrogen of the residue of an amino acid,

and wherein a blocking group AblC is covalently attached to the carbonyl group of the residue of an amino acid, wherein the blocking group AblC is selected from the group consisting of NH_2 and OH, or

b) the C-terminal dipeptide group,

wherein the residue of the first amino acid, the residue of the second amino acid or both the residue of the first and of the second amino acid optionally comprise a Z group,

and wherein a linker is optionally interspersed between the residue of Xaa11 and the residue of the first amino acid,

wherein if the interspersed linker is absent, the carbonyl group R^{11b} of residue Xaa11 is covalently attached to the α-nitrogen of the residue of the first amino acid and the carbonyl group of the residue of the first amino acid is covalently attached to the α-nitrogen of the residue of the second amino acid,

or wherein if the interspersed linker is present, the carbonyl group R^{11b} of residue Xaa11 is covalently attached to a nitrogen atom of the linker, a carbonyl group of the linker is covalently attached to the α-nitrogen of the residue of the first amino acid and the carbonyl group of the residue of the first amino acid is covalently attached to the α-nitrogen of the residue of the second amino acid,

and wherein a blocking group Abl is covalently attached to the carbonyl group of the residue of the second amino acid, wherein the blocking group AblC is selected from the group consisting of NH_2 and OH,

and

c) a Z group.

4. The compound of any one of claims 1 to 3,

wherein

(a)

Xaa7 is a residue of formula (VIIIa)


(VIIIa),

wherein

X^7 is –S– or –NH–,

q is 1 or 2,

Yc is a structure of formula (XIIIa)


(XIIIa),

wherein

R^{Ya} is $–CH_2–$,

R^{Yb} is $–CH_2–$,

Y^1 is selected from the group consisting of N and CH,

Y^2 is selected from the group consisting of CH and N,

and Xaa11 is a residue of formula (XIIa)


(XIIa),

wherein

X^{11} is –S– or –NH–,

R^{11b} is selected from the group consisting of $C(=O)R^{11c}$, $CONH_2$, CO_2H, CH_2OH and H, wherein R^{11c} is the C-terminal group C-term,

x is 1 or 2,

(b)

Xaa7 is a residue of formula (VIIIa)


(VIIIa),

wherein

X^7 is –S– or –NH–,

q is 1 or 2,

Yc is a structure of formula (XIIIh)


(XIIIh),

wherein

R^{Ya} is $–CH_2–$,

R^{Yb} is $–CH_2–$, and

R^{Yc} is $–CH_2–R^{Yd}$, and

R^{Yd} is a structure of formulae (XIIIc), (XIIId) or (XIIIe),


(XIIIc),

(XIIId),

(XIIIe),

wherein

R^{Ye} and R^{Yf} are each and independently selected from the group consisting of H and $(C_1\text{-}C_4)$alkyl,

i is each and independently 1, 2, 3, 4, 5 or 6,

j and k are each and independently 1, 2 or 3, and

X is O or S,

wherein

in formulae (XIIIc) and (XIIIe)

one of the two nitrogen atoms is covalently attached to $–CH_2–$ of R^{Yc}

and in formula (XIIId)

-X- is covalently attached to $-CH_2–$ of R^{Yc}

while to the remaining nitrogen atom optionally a Z group is covalently attached,

and Xaa11 is a residue of formula (XIIa)


(XIIa),

wherein

X^{11} is –S– or –NH–,

R^{11b} is selected from the group consisting of $C(=O)R^{11c}$, $CONH_2$, CO_2H, CH_2OH and H, wherein R^{11c} is the C-terminal group C-term,

x is 1 or 2,

(c)

Xaa7 is a residue of formula (VIIIa)


(VIIIa),

wherein

X^7 is –S– or –NH–,

q is 1 or 2,

Yc is a structure of formula (XIIIb)


(XIIIb),

wherein

R^{Ya} is $–CH_2–$,

R^{Yb} is $–CH_2–$,

and Xaa11 is a residue of formula (XIIa)


(XIIa),

wherein

X^{11} is –S– or –NH–,

R^{11b} is selected from the group consisting of $C(=O)R^{11c}$, $CONH_2$, CO_2H, CH_2OH and H, wherein R^{11c} is the C-terminal group C-term,

x is 1 or 2,

(d)

Xaa7 is a residue of formula (VIIIb)


(VIIIb),

wherein

q is 1 or 2,

Yc is a structure of formula (XIIIg)


(XIIIg),

wherein

R^{Yi} is selected from the group consisting of H and $(C_1\text{-}C_6)$alkyl,

and Xaa11 is a residue of formula (XIIb)


(XIIb),

wherein

R^{11b} is selected from the group consisting of $C(=O)R^{11c}$, $CONH_2$, CO_2H, CH_2OH and H, wherein R^{11c} is the C-terminal group C-term,

x is 1 or 2,

(e)

Yc is a structure of formula (XIIIf)

 (XIIIf),

wherein

R^{Yg} is –C(=O)–,

R^{Yh} is –CH_2–,

Xaa7 is a residue of formula (VIIIa)

 (VIIIa),

wherein

X^7 is –S– or –NH– and is covalently attached to R^{Yh},

q is 1 or 2,

and Xaa11 is a residue of formula (XIIa)

 (XIIa),

wherein

X^{11} is –NH– and is covalently attached to R^{Yg},

R^{11b} is selected from the group consisting of $C(=O)R^{11c}$, $CONH_2$, CO_2H, CH_2OH and H, wherein R^{11c} is the C-terminal group C-term,

x is 1 or 2,

(f)

Yc is a structure of formula (XIIIf)

 (XIIIf),

wherein

R^{Yg} is –C(=O)–,

R^{Yh} is –CH_2–,

Xaa7 is a residue of formula (VIIIa)



(VIIIa),

wherein

X^7 is –NH– and is covalently attached to R^{Yg},

q is 1 or 2,

and Xaa11 is a residue of formula (XIIa)



(XIIa),

wherein

X^{11} is –S– or –NH– and is covalently attached to R^{Yh},

R^{11b} is selected from the group consisting of $C(=O)R^{11c}$, $CONH_2$, CO_2H, CH_2OH and H, wherein R^{11c} is the C-terminal group C-term,

x is 1 or 2,

or

(g)

the compound comprises a cyclic peptide of formula (Ib), wherein

Xaa7 is a residue of formula (VIIIc)



(VIIIc),

and Xaa11 is a residue of formula (XIIc)



(XIIc),

wherein

R^{11b} is selected from the group consisting of $C(=O)R^{11c}$, $CONH_2$, CO_2H, CH_2OH and H, wherein R^{11c} is the C-terminal group C-term,

5. The compound of any one of claims 1 to 4, wherein Xaa1 is a residue of formula (IId) or (IIe),



(IId),



(IIe),

wherein

R^{1a} is selected from the group consisting of –NH–, H or $–N(CH_3)–$,

R^{1b} is selected from the group consisting of CO_2H, $CONH_2$, OH, SO_3H and OPO_3H_2,

under the proviso that R^{1a} is –NH– or $–N(CH_3)–$, the N-terminal modification group A is covalently attached to the nitrogen atom of R^{1a}.

6. The compound of any one of claims 1 to 5, wherein Xaa2 is a residue of an α-L-amino acid of formula (IIId),



(IIId),

wherein

X^{2a} is NH or S,

R^{2a} is H or F,

R^{2b} is selected from the group consisiting of H, F and Cl,

R^{2c} is selected from the group consisting of H, F, Cl, Br and OH,

7. The compound of any one of claims 1 to 6, wherein Xaa3 is a residue of an amino acid of formula (IVe) or (IVf),



(IVe)



(IVf)

wherein

R^{3b} is H or F,

R^{3c} is selected from the group consisting of Cl, Br, H and F,

X^{3a} is NH or S,

X^{3b} is selected from the group consisting of CH, CF and N, and

X^{3c} is CH or N,

.

8. The compound of any one of claims 1 to 7, wherein

(a)

Xaa4 is a residue of an amino acid of formula (Va)



(Va),

wherein

m is 1 or 2,

R^{4a} is selected from the group consisting of H, OH and methyl,

R^{4b} is either H or methyl,

X^4 is selected from the group consisting of CHR^{4c}, CH_2, S and O,

wherein R^{4c} is selected from the group consisting of NHR^{4d}, NH_2, H, OH, methyl and F,

wherein R^{4d} is Ac or is a Z group, ,

or

(b)

Xaa4 is a residue of an N-alkylated amino acid of formula (Vf)



(Vf),

wherein

n is 0, 1 or 3,

R^{4e} is selected from the group consisting of H and phenyl, if n = 0,

or is NH_2, if n = 3,

or is selected from the group consisting of methyl, CO_2H, and $C(=O)R^{4h}$, if n = 1,

wherein R^{4h} is a Z group, and

R^{4f} is selected from the group consisting of H and methyl,

or

(c)

Xaa4 is an Oic residue.

9. The compound of any one of claims 1 to 8, wherein Xaa5 is a residue of an α-amino acid optionally comprising a Z group, wherein the α-nitrogen atom of the α-amino acid is optionally substituted by a methyl group.

10. The compound of any one of claims 1 to 9, wherein Xaa6 is a residue of an amino acid of formula (VIIa)



(VIIa),

wherein

p is 1 or 0,

R^{6a} is (C_1-C_2)alkyl,

R^{6b} is methyl, and

R^{6c} is H if p is 0, and is H or methyl, if p is 1.

11. The compound of any one of claims 1 to 10, wherein

(a)

Xaa8 is a residue of an amino acid of formula (IXa),



(IXa),

wherein

r is 2 or 1,

X^8 is selected from the group consisting of NR^{8a}, O, NH, and CH_2,

wherein R^{8a} is a Z group or R^{8a} is acetyl, wherein if the Z group is a chelator optionally comprising a linker linker, the chelator is DOTA, or if the Z-group is a bio-distribution modifier optionally comprising a linker linker, the bio-distribution modifier is AGLU and the linker is Glutar, or if the Z group is a combination of a chelator optionally comprising a linker, a bio-distribution modifier optionally comprising a linker, and an amino acid residue linking the chelator optionally comprising a linker and the bio-distribution modifier optionally comprising a linker, the chelator is DOTA and the bio-distribution modifier is AGLU and the amino acid residue linking the chelator and the bio-distribution modifier is a glu residue,

(b) Xaa8 is an Aic residue,

(c) Xaa8 is a residue of an α-amino acid selected from the group consisting of Lys, Lys(R^{8e}), lys(R^{8e}), Amk(R^{8e}), Dab(R^{8e}) and dab(R^{8e}), wherein R^{8e} is a Z group, or

(d) Xaa8 is a residue of an α-amino acid residue selected from the group consisting of Aib, Deg, Ams, ala, Ala, Gln, Thr, Trp, Phe and Glu.

12. The compound of any one of claims 1 to 11, wherein Xaa9 is a residue of an amino acid of formula (Xa)



(Xa),

wherein

R^{9a} is selected from the group consisting of (C_1-C_4)alkyl, COOH, $CONH_2$, OH, NH_2, $NHC(=NH)NH_2$, an aryl ring and a heteroaryl ring,

R^{9b} is methyl or H,

R^{9c} is H or methyl, and

v is 0, 1, 2, .

13. The compound of any one of claims 1 to 12, wherein Xaa10 is a residue of an amino acid of formula (XIa)



(XIa),

wherein

R^{10a} is selected from the group consisting of (C_1-C_2)alkyl and phenyl,

R^{10b} is selected from the group consisting of methyl and H,

R^{10c} is selected from the group consisting of H and methyl, R^{10C} is H, if w is 1, and

w is 0 or 1, .

14. The compound of any one of claims 1 to 13, wherein the N-terminal modification group A

a) a Z group, wherein a linker is optionally interspersed between the Z group and Xaa1, wherein

the Z group is a chelator optionally comprising a linker ,

or the Z group is a bio-distribution modifier optionally comprising a linker,

or the Z group is a combination of

a chelator optionally comprising a linker,

a bio-distribution modifier optionally comprising a linker a linker,

and an amino acid residue linking the chelator optionally comprising a linker and the bio-distribution modifier optionally comprising a linker,

b) a blocking group AblN, wherein the blocking group AblN is selected from the group consisting of acetyl and a structure of formula (AblN-Ia),



(AblN-Ia),

wherein

R^{Abl1} is selected from the group consisting of H, OH and a halogen,

c) the residue of an amino acid, wherein the amino acid is an α-amino acid, wherein the residue of an amino acid

optionally comprises a Z group covalently attached to the side chain of the residue of an amino acid and optionally comprises a Z group covalently attached to the α-amino group of the residue of an amino acid,

or wherein the residue of an amino acid optionally comprises a blocking group AblN covalently attached to the α-amino group of the residue of an amino acid,

wherein the residue of an amino acid, with an optional Z group covalently attached to the α-amino group of the Tyr residue, wherein the Z group is a chelator comprising an optional linker, wherein the chelator is DOTA and the linker is Ttds,

d) the N-terminal dipeptide group,

wherein the residue of the first amino acid, the residue of the second amino acid or both the residue of the first and of the second amino acid optionally comprise a Z group,

wherein a blocking group AblN is optionally covalently attached to the α-amino group of the residue of the first amino acid,

and wherein a linker is optionally interspersed between the residue of the second amino acid and the residue of Xaa1,

wherein if the interspersed linker is absent, the carbonyl group of the residue of the first amino acid is covalently attached to the α-nitrogen of the residue of the second amino acid and the carbonyl group of the residue of the second amino acid is covalently attached to the nitrogen atom in R^{1a} or the α-nitrogen atom of residue Xaa1,

or wherein if the interspersed linker is present, the carbonyl group of the residue of the first amino acid is covalently attached to the α-nitrogen of the residue of the second amino acid and the carbonyl group of the residue of the second amino acid is covalently attached to a nitrogen atom of the linker and a carbonyl group of the linker is covalently attached to the nitrogen atom in R^{1a} or the α-nitrogen atom of residue Xaa1,

wherein the first amino acid residue is a Met residue and the residue of the second amino acid is selected from the group comprising Ala, Tyr and tyr,

15. The compound of claim 14, wherein the Z group is a bio-distribution modifier optionally comprising a linker, wherein the Z group isis selected from the group consisting of AGLU with Glutar as linker, NTASEROL, GLUSEROL with Glutar as linker, AHOL with Glutar as linker, APOL with Glutar as linker, ABOL with Glutar as linker, APrOL with Glutar as linker, MeO2kDaPEGAc, MeO10kDaPEGAc and MeO36PEG.

16. The compound of any one of claims 1 to 15, wherein the C-terminal group C-term is

a) the residue of an amino acid, wherein the amino acid is an α-amino acid,

optionally comprising a Z group and optionally comprising a linker interspersed between the residue of Xaa11 and the residue of an amino acid,

wherein if the interspersed linker is absent, the carbonyl group R^{11b} of residue Xaa11 is covalently attached to the α-nitrogen of the residue of an amino acid,

or wherein if the interspersed linker is present, the carbonyl group in R^{11b} of residue Xaa11 is covalently attached to a nitrogen atom of the linker, a carbonyl group of the linker is covalently attached to the α-nitrogen of the residue of an amino acid,

and wherein a blocking group AblC is covalently attached to the carbonyl group of the residue of an amino acid, wherein the blocking group AblC is selected from the group consisting of NH_2 and OH, or,

b) the C-terminal dipeptide group,

wherein the residue of the first amino acid is the residue of an α-amino acid and the residue of the second amino acid is the residue of an α-amino acid,

wherein the residue of the first amino acid, the residue of the second amino acid residue or both the residue of the first and of the second amino acid optionally comprise a Z group,

and wherein a linker is optionally interspersed between the residue of Xaa11 and the residue of the first amino acid,

wherein if the interspersed linker is absent, the carbonyl group R^{11b} of Xaa11 is covalently attached to the α-nitrogen of the residue of the first amino acid and the carbonyl group of the residue of the first amino acid is covalently attached to the α-nitrogen of the residue of the second amino acid,

or wherein if the interspersed linker is present, the carbonyl group R^{11b} of Xaa11 is covalently attached to a nitrogen atom of the linker, a carbonyl group of the linker is covalently attached to the α-nitrogen of the residue of the first amino acid and the carbonyl group of the residue of the first amino acid is covalently attached to the α-nitrogen of the residue of the second amino acid,

and wherein a blocking group AblC is covalently attached to the carbonyl group of the residue of the second amino acid, wherein the blocking group AblC is selected from the group consisting of NH_2 and OH, or

c) a Z group.

17. The compound of any one of claims 1 to 16, wherein the C-terminal group C-term is the residue of an α-amino acid, wherein the α-amino acid is selected from

i) an α-amino acid comprising a side chain AaaA, wherein the side chain comprises an amino group, wherein to the amino group a Z group is covalently attached by an amide bond, wherein the Z group is a chelator optionally comprising a linker, wherein the chelator is selected from the group consisting of DOTA, DOTAGA, DOTAM, DOTP, NOTA, NODAGA, PSC, NODA-MPAA, HBED, TETA, CB-TE2A, DTPA, CHX-A''-DTPA, DFO, Macropa, HOPO, TRAP, THP, DATA, NOPO, NOTP, PCTA,

sarcophagine, FSC, NETA, NE3TA, H4octapa, pycup, HYNIC, NxS4 x (N4, N2S2, N3S), 99mTc(CO)$_3$-chelators and their analogs,

or

ii) an α-amino acid comprising a side chain AaaB, wherein the side chain comprises an amino group, wherein to the amino group a Z group is covalently attached by an amide bond, wherein the Z group is a bio-distribution modifier optionally comprising a linker, wherein the Z group

a) is selected from the group consisting of AGLU with Glutar as linker, NTASEROL, GLUSEROL with Glutar as linker, AHOL with Glutar as linker, APOL with Glutar as linker, ABOL with Glutar as linker, APrOL with Glutar as linker, MeO2kDaPEGAc, MeO10kDaPEGAc and MeO36PEG,

or

iii) an α-amino acid comprising a side chain AaaC, wherein the side chain comprises a COOH group, where to the COOH group a Z group is covalently attached by an amide bond, wherein the Z group is a bio-distribution modifier optionally comprising a linker, wherein the bio-distribution modifier is selected from the group consisting of AGLU, GLUSEROL, AHOL, APOL, ABOL, and APrOL;

wherein the blocking group AblC is NH_2,
and wherein an optional linker is interspersed between Xaa11 and the residue of the α-amino acid.

18. The compound of any one of claims 1 to 17, wherein the compound comprises one Z group, two Z groups, three Z groups or four Z groups.

19. The compound of claim 18, wherein the compound comprises three Z groups, wherein

one of the three Z groups is a chelator optionally comprising a linker, and the other two of the three Z groups are bio-distribution modifiers optionally comprising a linker, wherein the chelator optionally comprising a linker

a) is covalently attached to or is part of substituent R^{8a}, under the proviso that residue Xaa8 is a structure of formula (XIa), (IXd) or (IXe),

b) is covalently attached to or is part of substituent R^{8e}, under the proviso that residue Xaa8 is a structure of formula (XIc),

c) is covalently attached to the residue of an α-amino acid of the C-terminal group C-term,

or

d) is part of or forms the N-terminal modification group A,

and wherein either of the two the bio-distribution modifiers optionally comprising a linker

a) is covalently attached to or is part of substituent R^{8a}, under the proviso that residue Xaa8 is a structure of formulae (XIa), (IXd) or (IXe),

b) is covalently attached to or is part of substituent R^{8e}, under the proviso that residue Xaa8 is a structure of formula (XIc),

c) is covalently attached to the residue of an α-amino acid of the C-terminal group C-term,

or

d) is part of or forms the N-terminal modification group A,

and wherein one of the two bio-distribution modifiers each optionally comprising a linker is part of or forms the N-terminal modification group A,

and wherein the other of the two bio-distribution modifiers each optionally comprising a linker is covalently attached to the residue of an α-amino acids of the C-terminal group C-term.

20. The compound of any one of claims 1 to 4,

wherein

Xaa1 is Asp, Asn, Glu, Gln, Succinyl, Glutar or Cya,

Xaa2 is Trp, Hyw, 5Fw, 6Clw or 7Fw,

Xaa3 is 5Clw, 5Brw, 5Fw, Trp, 1Ni, Bta, 6Fw or Trp,

Xaa4 is Tap, Hyp, 4Tfp, Pro, H3p, Eaz, Oxa, Dtc, Nmg, Nleu, Nlys, Nphe or Nglu,

Xaa5 is Glu, glu, Nme, Gln, Asp, Asn or Hse,

Xaa6 is leu, Leu, Npg, Val or Ile,

Xaa7 is Cys or Hcy,

Xaa8 is Apc(DOTA), Thp, Apc, Aib, Deg, Ams, Amk(DOTA), Egz, Eca, or ala,

Xaa9 is Leu, Hle, Ile, Phe, Glu, Arg, Ser or Trp,

Xaa10 is Ile, Leu, Val or Tle,

Xaa11 is Cys, Hcy or AET, and

Yc is 3MeBn or 3Lut, or

wherein

Xaa1 is Asp, Glu or Succinyl,

Xaa2 is Trp or Hyw,

Xaa3 is 5Clw or 5Brw,

Xaa4 is Tap, Hyp, or Pro,

Xaa5 is Glu,

Xaa6 is leu or Leu,

Xaa7 is Cys,

Xaa8 is Apc(DOTA) or Thp,

Xaa9 is Leu,

Xaa10 is Ile

Xaa11 is Cys and

Yc is 3Lut, or

wherein

Xaa1 is Asp,

Xaa2 is Trp,

Xaa3 is 5Clw,

Xaa4 is Tap or Hyp,

Xaa5 is Glu,

Xaa6 is leu,

Xaa7 is Cys,

Xaa8 is Apc(DOTA),

Xaa9 is Leu,

Xaa10 is Ile

Xaa11 is Cys and

Yc is 3Lut.

21. The compound of claim 20, wherein the compound comprises three Z groups, wherein a first of the three Z groups is a chelator,

wherein the chelator is covalently attached to Xaa8,

wherein Xaa8 is a Apc residue and wherein the chelator is DOTA,

and

wherein a second of the three Z groups is bio-distribution modifier optionally comprising a linker,

wherein the bio-distribution modifier and the linker form the N-terminal modification group A,

wherein the N-terminal modification group A is AGLU-Glutar,

and

wherein a third of the three Z groups is a bio-distribution modifier,

wherein the bio-distribution modifier is covalently attached to the residue of an α-amino acid of the C-terminal group C-term

and wherein the C-terminal group C-term is APAc-glu(AGLU)-NH_2.

22. The compound of any one of claims 1 to 21, wherein the compound is selected from the group consisting of compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-001) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-002) of the following formula



,

compound DOTA-glu(AGLU)-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(AGLU-Glutar)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-003) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-Lys(DOTA)-NH_2 (GIP-004) of the following formula



,

compound DOTA-glu(AGLU)-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-005) of the following formula



compound AGLU-Glutar-APAc-Asp-Trp-5Clw-Tap(AGLU-Glutar)-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-006) of the following formula



compound AGLU-Glutar-APAc-Asp-Trp-5Clw-Tap(AGLU-Glutar)-Glu-leu-[Cys(2Lut)-Apc(DOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-007) of the following formula



compound AGLU-Glutar-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-008) of the following formula



,

compound DOTA-glu(AGLU)-O2Oc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(AGLU-Glutar)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-009) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(AGLU-Glutar)-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH_2 (GIP-010) of the following formula



,

compound AGLU-Glutar-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-011) of the following formula



,

compound DOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(AGLU-Glutar)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-012) of the following formula



,

compound AGLU-Glutar-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-013) of the following formula



,

compound AGLU-Glutar-APAc-Asp-Trp-5Brw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-014) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Brw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-015) of the following formula



,

compound AGLU-Glutar-Hse-Trp-5Brw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-016) of the following formula



,

compound DOTA-glu(AGLU)-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-017) of the following formula



,

compound DOTA-O2Oc-glu(AGLU)-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-018) of the following formula



,

compound DOTA-glu(AGLU)-PEG6-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-019) of the following formula



,

compound DOTA-glu(AGLU)-O2Oc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-020) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-Lys(DOTA)-NH_2 (GIP-021) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc-Leu-Ile-Cys]-APAc-glu(AGLU)-Lys(DOTA)-NH_2 (GIP-022) of the following formula



compound HO-Succinyl-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-023) of the following formula



compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Lys(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-024) of the following formula



compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-lys(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-025) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Dab(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-026) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-dab(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-027) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(NODAGA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-028) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(NOPO)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-029) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(N4Ac)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-030) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(NODAGA-Gly)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-031) of the following formula



compound AGLU-Glutar-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-glu(AGLU)-NH_2 (GIP-033) of the following formula



compound AGLU-Glutar-Hse-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-034) of the following formula



compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-Leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-035) of the following formula



,

compound DOTA-glu(AGLU)-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-036) of the following formula



,

compound DOTA-PEG6-glu(AGLU)-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-037) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-cys]-APAc-glu(AGLU)-NH_2 (GIP-038) of the following formula



,

compound AGLU-Glutar-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-lys(MeO36PEG)-NH_2 (GIP-039) of the following formula



,

compound MeO36PEG-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-glu(AGLU)-NH_2 (GIP-040) of the following formula



,

compound MeO36PEG-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-041) of the following formula



,

compound MeO36PEG-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-042) of the following formula



,

compound AGLU-Glutar-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-043) of the following formula



,

compound DOTA-O2Oc-glu(AGLU)-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(AGLU-Glutar)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-044) of the following formula



,

compound DOTA-glu(AGLU)-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(AGLU-Glutar)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-045) of the following formula



,

compound AGLU-Glutar-APAc-Ser-Trp-5Clw-Tap(AGLU-Glutar)-Hse-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-046) of the following formula



,

compound AGLU-Glutar-APAc-Hse-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-047) of the following formula



,

compound AGLU-Glutar-APAc-Ser-Trp-5Clw-Tap-Hse-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-048) of the following formula



,

compound AGLU-Glutar-APAc-Hse-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-049) of the following formula



compound AGLU-Glutar-APAc-Hse-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-050) of the following formula



compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-051) of the following formula



compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[cys(2Lut)-Apc(DOTA)-Leu-Ile-cys]-APAc-glu(AGLU)-NH_2 (GIP-052) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Apc(DOTA)-Leu-Ile-AET] (GIP-053) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-Lys(DOTA)-NH_2 (GIP-054) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-Lys(DOTA)-NH_2 (GIP-055) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Tap(DOTA)-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-Lys(DOTA)-NH_2 (GIP-056) of the following formula



,

compound AGLU-Glutar-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(GaDOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-059) of the following formula



,

compound AGLU-Glutar-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(InDOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-060) of the following formula



,

compound AGLU-Glutar-APAc-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(LuDOTA-glu(AGLU))-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-061) of the following formula



,

compound LuDOTA-glu(AGLU)-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-062) of the following formula



,

compound InDOTA-glu(AGLU)-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-063) of the following formula



,

compound EuDOTA-glu(AGLU)-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-064) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(InDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-065) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(LuDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-066) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(LuDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-067) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(InDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-068) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(GaDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-069) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(GaDOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-070) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(GaNODAGA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-071) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-AET] (GIP-072) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(AGLU-Glutar)-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH_2 (GIP-073) of the following formula



,

compound Ac-Asp-Trp-1Ni-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-074) of the following formula



,

compound Ac-Asp-Trp-Bta-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-075) of the following formula



,

compound Ac-Asp-Trp-5Clw-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-076) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-077) of the following formula



,

compound Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-078) of the following formula



,

compound Ac-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-079) of the following formula



,

compound Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Egz-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-080) of the following formula



,

compound Ac-Asp-Trp-5Fw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-081) of the following formula



,

compound Ac-Asp-Trp-5Brw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-082) of the following formula



,

compound Ac-Asp-5Fw-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-083) of the following formula



,

compound Ac-Asp-6Fw-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-084) of the following formula



,

compound HO-Succinyl-Trp-1Ni-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-085) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Egz-Leu-Ile-AET] (GIP-086) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Thp-Leu-Ile-AET] (GIP-087) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Apc-Leu-Ile-AET] (GIP-088) of the following formula



,

compound DOTA-APAc-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-089) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(2Lut)-Aib-Leu-Ile-AET] (GIP-090) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3Lut)-Aib-Leu-Ile-AET] (GIP-091) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Dap(3MeBn)-Aib-Leu-Ile-AET] (GIP-092) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-en] (GIP-093) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-094) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-095) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-4Ap-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-096) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Apc(Ac)-Leu-Ile-AET] (GIP-097) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Dap(3MeBn)-Aib-Leu-Ile-AETO] (GIP-098) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Hle-Ile-AET] (GIP-099) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Nmg-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-100) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Ams-Leu-Ile-AET] (GIP-101) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-H3p-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-102) of the following formula



,

compound DOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-AET] (GIP-103) of the following formula



,

compound DOTA-Ttds-Asp-6Fw-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-104) of the following formula



,

compound DOTA-Ttds-Asp-6Fw-5Brw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-105) of the following formula



,

compound DOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Dap(2Lut)-Thp-Leu-Ile-AET] (GIP-106) of the following formula



,

compound DOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Dap(3MeBn)-Thp-Leu-Ile-AET] (GIP-107) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-108) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH_2 (GIP-109) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-AET] (GIP-110) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-4Ap(Ac)-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-111) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc-Leu-Ile-AET] (GIP-112) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Tap-Glu-leu-[Dap(2Lut)-Apc-Leu-Ile-AET] (GIP-113) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH_2 (GIP-114) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-Lys(DOTA)-NH_2 (GIP-115) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-lys(DOTA)-NH_2 (GIP-116) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-Ape-DOTA (GIP-117) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-PP-DOTA (GIP-118) of the following formula



compound DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(2Lut)-Apc-Leu-Ile-AET] (GIP-119) of the following formula



compound MeO2kDaPEGAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-lys(DOTA)-NH_2 (GIP-120) of the following formula



compound Ac-Asp-Trp-5Clw-Tap(DOTA)-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-121) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-NH_2 (GIP-122) of the following formula



,

compound Ac-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-NH_2 (GIP-123) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(tMeBn(DOTA-AET))-Thp-Leu-Ile-Cys]-NH_2 (GIP-124) of the following formula



,

compound DOTA-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-125) of the following formula



,

compound DOTA-Ttds-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH_2 (GIP-126) of the following formula



,

compound Ac-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-127) of the following formula



,

compound DOTA-Ttds-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH_2 (GIP-128) of the following formula



,

compound DOTA-Ttds-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-129) of the following formula



,

compound DOTA-Ttds-Nmd-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-130) of the following formula



,

compound Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-131) of the following formula



,

compound Ac-Asp-Trp-Trp-Pro-Glu-Npg-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-132) of the following formula



,

compound Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Npg-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-133) of the following formula



,

compound Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Cha-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-134) of the following formula



,

compound Php-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-135) of the following formula



,

compound 4FPhp-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-136) of the following formula



,

compound 4OHPhp-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-137) of the following formula



,

compound Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Ala-Leu-Val-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-138) of the following formula



,

compound Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Deg-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-139) of the following formula



,

compound Ac-Asp-Trp-6Fw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-140) of the following formula



,

compound DOTA-Ttds-Asp-6Clw-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-141) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(MeO10kDaPEGAc)-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH_2 (GIP-142) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(MeO2kDaPEGAc)-Leu-Ile-Cys]-APAc-Lys(DOTA)-NH_2 (GIP-143) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-lys(MeO2kDaPEGAc)-Lys(DOTA)-NH_2 (GIP-144) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(tMeBn(DOTA-PP))-Thp-Leu-Ile-Cys]-NH_2 (GIP-145) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(InDOTA)-Leu-Ile-AET] (GIP-146) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(ZnDOTA)-Leu-Ile-AET] (GIP-147) of the following formula



,

compound InDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-148) of the following formula



,

compound InDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Ams-Leu-Ile-AET] (GIP-149) of the following formula



,

compound InDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Thp-Leu-Ile-AET] (GIP-150) of the following formula



,

compound InDOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-151) of the following formula



,

compound InDOTA-Ttds-Asp-Trp-5Clw-Nmg-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-152) of the following formula



,

compound InDOTA-APAc-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-153) of the following formula



,

compound InDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(2Lut)-Aib-Leu-Ile-AET] (GIP-154) of the following formula



,

compound InDOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-AET] (GIP-155) of the following formula



,

compound Ac-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(LuDOTA)-NH_2 (GIP-156) of the following formula



,

compound LuDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Ams-Leu-Ile-AET] (GIP-157) of the following formula



,

compound LuDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Thp-Leu-Ile-AET] (GIP-158) of the following formula



,

compound LuDOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-159) of the following formula



,

compound LuDOTA-Ttds-Asp-Trp-5Clw-Nmg-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-160) of the following formula



,

compound LuDOTA-APAc-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-161) of the following formula



,

compound LuDOTA-APAc-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-AET] (GIP-162) of the following formula



,

compound LuDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(2Lut)-Aib-Leu-Ile-AET] (GIP-163) of the following formula



,

compound Ac-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(InDOTA)-NH_2 (GIP-164) of the following formula



,

compound Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(InDOTA)-NH_2 (GIP-165) of the following formula



,

compound Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Egz-Leu-Ile-Cys]-Ttds-Lys(InDOTA)-NH_2 (GIP-166) of the following formula



,

compound LuDOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-167) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-Lys(InDOTA)-NH_2 (GIP-168) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(InDOTA)-Leu-Ile-AET] (GIP-169) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-Lys(LuDOTA)-NH_2 (GIP-170) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(LuDOTA)-Leu-Ile-AET] (GIP-171) of the following formula



,

compound Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(LuDOTA)-NH_2 (GIP-172) of the following formula



,

compound Ac-Asp-Trp-1Ni-Pro-Glu-leu-[Cys(3MeBn)-Egz-Leu-Ile-Cys]-Ttds-Lys(LuDOTA)-NH_2 (GIP-173) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-174) of the following formula



,

compound Ac-Asp-Trp-5Clw-Tap(AGLU-Glutar)-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-175) of the following formula



,

compound Ac-Asp-Trp-5Clw-Nglu(AGLU)-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-176) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-177) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-178) of the following formula



,

compound Ac-Cya-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Aib-Leu-Ile-AET] (GIP-179) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-180) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-OH (GIP-181) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cysol]-OH (GIP-182) of the following formula



,

compound Ac-Asp-Trp-5Clw-Nmg-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-183) of the following formula



,

compound Ac-Asp-Trp-5Clw-Nleu-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-184) of the following formula



,

compound Ac-Asp-Trp-5Clw-Nphe-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-185) of the following formula



,

compound Ac-Asp-Trp-5Clw-Nlys-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-186) of the following formula



,

compound Ac-Asp-Trp-5Clw-4Tfp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-187) of the following formula



,

compound Ac-Ser-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-188) of the following formula



,

compound Ac-Cya-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-189) of the following formula



,

compound Ac-Asn-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-190) of the following formula



,

compound Ac-Glu-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-191) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Asp-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-192) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Gln-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-193) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Hse-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-194) of the following formula



,

compound Ac-Hse-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-195) of the following formula



,

compound Ac-Asp-Trp-5Clw-Nglu-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-196) of the following formula



,

compound Ac-Hse-Trp-5Brw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-197) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH_2 (GIP-198) of the following formula



,

compound HO-Succinyl-Trp-5Clw-Pro-Glu-leu-[Cys(3MeBn)-Thp-Leu-Ile-Cys]-NH_2 (GIP-199) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Hcy(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-200) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Hcy]-NH_2 (GIP-201) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Hcy(2Lut)-Thp-Leu-Ile-Hcy]-NH_2 (GIP-202) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Eca-Leu-Ile-Cys]-NH_2 (GIP-203) of the following formula



,

compound Ac-Gln-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-204) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Asn-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-205) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Aic-Leu-Ile-Cys]-NH_2 (GIP-206) of the following formula



,

compound Ac-Pse-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-207) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Pse-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-208) of the following formula



,

compound Ac-Asp-Mcf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-209) of the following formula



,

compound Ac-Asp-Pcf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-210) of the following formula



,

compound Ac-Asp-Eaa-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-211) of the following formula



,

compound Ac-Asp-Egm-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-212) of the following formula



,

compound Ac-Asp-Trp-Eaa-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-213) of the following formula



,

compound HO-Glutar-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-214) of the following formula



,

compound Ac-Asp-Trp-5Clw-Dtc-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-215) of the following formula



,

compound Ac-Asp-Trp-5Clw-Oxa-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-216) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Nme-Leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-217) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-Ile-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-218) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-Val-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-219) of the following formula



,

compound Ac-Asp-Hyw-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-220) of the following formula



,

compound Ac-Asp-7Fw-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-221) of the following formula



,

compound Ac-Asp-Trp-5Clw-Eaz-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-222) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-glu-Leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-223) of the following formula



,

compound Ac-Asp-Phe-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-224) of the following formula



,

compound Ac-Asp-Egp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-226) of the following formula



,

compound Ac-Asp-Trp-7Fw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-227) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Phe-Leu-Ile-Cys]-NH_2 (GIP-228) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Ile-Ile-Cys]-NH_2 (GIP-229) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Arg-Ile-Cys]-NH_2 (GIP-230) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Glu-Ile-Cys]-NH_2 (GIP-231) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Phe-Ile-Cys]-NH_2 (GIP-232) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Trp-Ile-Cys]-NH_2 (GIP-233) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Trp-Leu-Ile-Cys]-NH_2 (GIP-234) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Glu-Leu-Ile-Cys]-NH_2 (GIP-235) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Ser-Ile-Cys]-NH_2 (GIP-236) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Leu-Cys]-NH_2 (GIP-237) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Tle-Cys]-NH_2 (GIP-238) of the following formula



,

compound Ac-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-239) of the following formula



,

compound Ac-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH_2 (GIP-240) of the following formula



,

compound H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Gln-Leu-Ile-Cys]-NH_2 (GIP-241) of the following formula



,

compound H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Thr-Leu-Ile-Cys]-NH_2 (GIP-242) of the following formula



,

compound H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Lys-Leu-Ile-Cys]-NH_2 (GIP-243) of the following formula



,

compound Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH_2 (GIP-244) of the following formula



,

compound H-Met-Tyr-Asp-Trp-Trp-Pro-glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH_2 (GIP-245) of the following formula



,

compound H-Met-tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH_2 (GIP-246) of the following formula



,

compound H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH_2 (GIP-247) of the following formula



,

compound H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-ala-Leu-Ile-Cys]-NH_2 (GIP-248) of the following formula



,

compound H-Met-Ala-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH_2 (GIP-249) of the following formula



,

compound Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-ala-Leu-Ile-AET] (GIP-250) of the following formula



,

compound Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-251) of the following formula



,

compound Ac-Asp-Trp-1Ni-Oic-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH_2 (GIP-252) of the following formula



,

compound Ac-Asp-Trp-1Ni-Pip-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH_2 (GIP-253) of the following formula



,

compound H-Met-Tyr-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH_2 (GIP-254) of the following formula



,

compound HO-Succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-Cys]-NH_2 (GIP-255) of the following formula



,

compound HO-Succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Ala-Leu-Ile-AET] (GIP-256) of the following formula



,

compound HO-Succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(2Lut)-Ala-Leu-Ile-Cys]-NH_2 (GIP-257) of the following formula



,

compound HO-Succinyl-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH_2 (GIP-258) of the following formula



,

compound HO-Succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH_2 (GIP-259) of the following formula



,

compound HO-Succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Hle-Ile-Cys]-NH_2 (GIP-260) of the following formula



,

compound HO-Succinyl-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Thp-Leu-Ile-Cys]-NH_2 (GIP-261) of the following formula



,

compound Ac-Asp-Ocf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-262) of the following formula



,

compound Ac-Asp-Egn-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-263) of the following formula



,

compound Ac-Asp-Trp-Egp-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-265) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Phe-Cys]-NH_2 (GIP-266) of the following formula



,

compound Ac-Asp-Trp-7Nw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-267) of the following formula



,

compound DOTA-Ttds-Asp-Trp-Trp-Pro-glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH_2 (GIP-270) of the following formula



,

compound DOTA-Ttds-asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-ala-Leu-Ile-Cys]-NH_2 (GIP-271) of the following formula



,

compound Ac-Asp-Bta-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-273) of the following formula



,

compound Ac-Asp-Trp-Trp-Pro-Nme-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-274) of the following formula



,

compound Ac-Asp-Trp-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Tle-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-276) of the following formula



,

compound Ac-Asp-5Clw-Trp-Pro-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-277) of the following formula



,

compound 4ClPhp-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-279) of the following formula



,

compound Nph2p-Asp-Trp-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-281) of the following formula



,

compound Ac-Asp-Trp-6Clw-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-Ttds-Lys(DOTA)-NH_2 (GIP-282) of the following formula



,

compound DOTA-Ttds-Asp-6Fw-Trp-Pro-Glu-leu-[Cys(3MeBn)-Aib-Leu-Ile-AET] (GIP-283) of the following formula



,

compound Ac-Asp-Trp-1Ni-Pro-Glu-Hle-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH_2 (GIP-315) of the following formula



,

compound HO-Succinyl-Trp-Trp-Hyp-Glu-Leu-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH_2 (GIP-319) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Dap(3MeBz)-Aib-Leu-Ile-AET] (GIP-358) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Pro-Glu-leu-[Cys(3CbBn)-Aib-Leu-Ile-en] (GIP-359) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(mli)-Thp-Leu-Ile-Cys]-NH_2 (GIP-360) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(mli)-Thp-Leu-Ile-Hcy]-NH_2 (GIP-361) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Hcy(mli)-Thp-Leu-Ile-Cys]-NH_2 (GIP-362) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Hcy-Thp-Leu-Ile-Hcy]-NH_2 (GIP-363) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTAM)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-370) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Amk(DOTA)-Leu-Ile-Cys]-APAc-glu(AGLU)-NH_2 (GIP-371) of the following formula



,

compound AGLU-Glutar-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-GLUSEROL (GIP-372) of the following formula



,

compound NTASEROL-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-dap(NTASEROL)-NH_2 (GIP-373) of the following formula



,

compound NTASEROL-Asp-Trp-5Clw-Tap-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-APAc-GLUSEROL (GIP-374) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Lys-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-375) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Arg-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-376) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-His-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-377) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Hly-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-378) of the following formula



,

compound Ac-Asp-5Clw-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-379) of the following formula



,

compound Ac-Asp-1Ni-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-380) of the following formula



,

compound Ac-asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-381) of the following formula



,

compound Ac-Asp-5Fw-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-382) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Cha-Ile-Cys]-NH_2 (GIP-383) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Ser-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-384) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Val-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-385) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Ala-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-386) of the following formula



,

compound DOTA-Ttds-Asp-Ocf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-387) of the following formula



,

compound DOTA-Ttds-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Phe-Cys]-NH_2 (GIP-388) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Phe-Cys]-lys(DOTA)-NH_2 (GIP-389) of the following formula



,

compound Ac-Asp-Ocf-5Clw-Tap(DOTA)-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-390) of the following formula



,

compound Ac-Asp-Trp-5Clw-Tap(DOTA)-Glu-leu-[Cys(2Lut)-Thp-Leu-Phe-Cys]-NH_2 (GIP-391) of the following formula



,

compound Ac-Asp-Ocf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Ile-Cys]-NH_2 (GIP-392) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Apc(DOTA)-Leu-Phe-Cys]-NH_2 (GIP-393) of the following formula



,

compound Ac-Asp-Trp-1Ni-Tap(DOTA)-Glu-Hle-[Cys(3MeBn)-Aib-Leu-Ile-Cys]-NH_2 (GIP-394) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Har-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-395) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Phe-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-396) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Trp-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-397) of the following formula



,

compound Ac-Asp-Trp-5Clw-Hyp-Pro-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-NH_2 (GIP-398) of the following formula



,

compound Ac-Asp-Ocf-5Clw-Hyp-Glu-leu-[Cys(2Lut)-Thp-Leu-Ile-Cys]-lys(DOTA)-NH_2 (GIP-399) of the following formula



,

and compound Ac-Asp-Trp-1Ni-Pro-Glu-Hle-[Cys(3MeBn)-Apc(DOTA)-Leu-Ile-Cys]-NH_2 (GIP-400) of the following formula



23. The compound of claim 22, wherein the compoundis selected from the group consisting of GIP-001 to GIP-031, GIP-033 to GIP-056, GIP-059 to GIP-224, GIP-226 to GIP-263, GIP-265 to GIP-267, GIP-270, GIP-271, GIP-273, GIP-274, GIP-276, GIP-277, GIP-279, GIP-281, GIP-283, GIP-315, GIP-319, GIP-358, GIP-359, GIP-363 and GIP-370 to GIP-400.

24. The compound of any one of claims 1 to 23, wherein any S-atom, which can be oxidized is present as -S-, -S(O)- or -S(O_2)- or mixture thereof.

25. The compound of any one of claims 1 to 24, wherein the compound comprises a radionuclide, wherein the radionuclide is a radionuclide suitable for diagnosis.

26. The compound of claim 25, wherein the radionuclide

is selected from the group comprising, ^{43}Sc, ^{44}Sc, ^{51}Mn, ^{52}Mn, ^{64}Cu, ^{67}Ga, ^{68}Ga, ^{86}Y, ^{89}Zr, ^{94m}Tc, ^{99m}Tc, ^{111}In, ^{152}Tb, ^{155}Tb, ^{177}Lu, ^{201}Tl, ^{203}Pb, ^{18}F, ^{76}Br, ^{77}Br, ^{123}I, ^{124}I, and ^{125}I.

27. The compound of any one of claims 1 to 24, wherein the compound comprises a radionuclide, wherein the radionuclide is a radionuclide suitable for therapy.

28. The compound of claim 27, wherein the radionuclide is selected from the group comprising ^{47}Sc, ^{67}Cu, ^{89}Sr, ^{90}Y, ^{111}In, ^{153}Sm, ^{149}Tb, ^{161}Tb, ^{177}Lu, ^{186}Re, ^{188}Re, ^{212}Pb, ^{213}Bi, ^{223}Ra, ^{225}Ac, ^{226}Th, ^{227}Th, ^{131}I, and ^{211}At.

29. Use of a compound of any one of claims 25 to 26 in the manufacture of a medicament for the diagnosis of a disease, wherein the disease is selected from the group consisting of a cancer and a metabolic diseases.

30. Use of a compound of any one of claims 27 to 28 in the manufacture of a medicament for the treatment of a disease, wherein the disease is selected from the group consisting of a cancer and a metabolic disease.

31. The use of claim 29, wherein the medicament is for the identification of a subject, wherein the subject is likely to respond or likely not to respond to a treatment of the disease.

32. The use of claim 29, wherein the medicament is for the selection of a subject from a group of subjects, wherein the subject is likely to respond or likely not to respond to a treatment of the disease.

33. The use of claim 29, wherein the medicament is for the stratification of a group of subjects into subjects which are likely to respond to a treatment of the disease, and into subjects which are not likely to respond to a treatment of the disease.

34. The use of any one of claims 29 to 33, wherein the disease is cancer.

35. The use of claim 34, wherein the cancer is expressing or overexpressing Gastric Inhibitory Peptide Receptor (GIPR).

36. The use of any one of claims 34 and 35, wherein the cancer is a neuroendocrine cancer or a neuroendocrine neoplasm.

37. The use of any one of claims 34 to 36, wherein the cancer is selected from the group consisting of medullary thyroid cancer, gastrointestinal neuroendocrine neoplasms, ileal neuroendocrine neoplasms, pancreatic neuroendocrine neoplasms, nonfunctioning neuroendocrine neoplasms, Insulinomas, Gastrinomas, Glucagonomas, VIPomas, Somatostatinoma, ACTHoma, lung neuroendocrine neoplasms, typical carcinoid tumors,

atypical carcinoid tumors, small cell carcinoma of the lung, large cell carcinoma of the lung, thymic neuroendocrine tumors, Merkel cell carcinoma, Pheochromocytoma of the adrenal gland, adrenal cancer, parathyroid cancer, paraganglioma, pituitary gland tumors, neuroendocrine tumors of the ovaries and neuroendocrine tumors of the testicles.

38. The use of any one of claims 29 to 33, wherein the disease is a metabolic disease.

39. The use of claim 38, wherein a diseased cell and/or a diseased tissue expresses GIPR.

40. The use of claim 39, wherein the diseased cell and/or the diseased tissue overexpresses GIPR.

41. The use of any one of claims 39 to 40, wherein the diseased cell is a pancreatic cell.

42. The use of any one of claims 38 to 41, wherein the metabolic disease is selected from the group consisting of type 2 diabetes, type 1 diabetes, metabolic syndrome, insulin resistance, dyslipidemia, impaired fasting glucose, and impaired glucose tolerance.

43. A composition comprising a compound of any one of claims 1 to 28 and a pharmaceutically acceptable excipient.

44. The composition of claim 43, wherein the composition is a pharmaceutical composition.

45. A kit comprising a compound of any one of claims 1 to 28 and one or more optional excipient(s) and optionally one or more device(s).

46. The kit of claim 45, wherein the device(s) is/are selected from the group comprising a labeling device, a purification device, a handling device, a radioprotection device, an analytical device or an administration device.